Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804640 | 0.92 | SMO (0.50) | SMOHTR2CHTR2BEIF2AK3MAPT | |
| SCHEMBL6809248 | 0.90 | SMO (0.56) | SMOHTR2CHTR2BEIF2AK3AVPR2 | |
| SCHEMBL6805188 | 0.88 | HTR2C (0.51) | SMOHTR2CHTR2BEIF2AK3EIF2AK1 | |
| SCHEMBL6805171 | 0.88 | SMO (0.52) | SMOHTR2CHTR2BEIF2AK3EIF2AK2 | |
| SCHEMBL6664230 | 0.88 | GAA (0.48) | SMOHTR2CHTR2BEIF2AK3MAPT | |
| SCHEMBL6668503 | 0.87 | EIF2AK3 (0.51) | SMOHTR2CHTR2BEIF2AK3MAPT | |
| SCHEMBL6804049 | 0.87 | SMO (0.50) | SMOHTR2CHTR2BEIF2AK3MAPT | |
| SCHEMBL6803784 | 0.87 | EIF2AK3 (0.53) | SMOHTR2CHTR2BEIF2AK3EIF2AK1 | |
| SCHEMBL6804470 | 0.87 | SMO (0.50) | SMOHTR2CHTR2BEIF2AK3EIF2AK1 | |
| SCHEMBL6800472 | 0.86 | EIF2AK3 (0.49) | SMOHTR2CHTR2BEIF2AK3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | SMO 4390/4885HTR2C 2433/4885HTR2B 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.